Skip to main content

Parabilis Medicines, Inc 8-K, filed Nov 12, 2026

Parabilis Medicines, Inc. (PBLS)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Parabilis Medicines, Inc filed this 8-K on November 12, 2026.

Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits